Information  X 
Enter a valid email address

Novacyt S.A. (NCYT)

  Print   

Friday 25 March, 2022

Novacyt S.A.

Director/PDMR Shareholding

RNS Number : 1357G
Novacyt S.A.
25 March 2022
 

 

 

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Director/PDMR Shareholding

 

Paris, France and Camberley, UK - 25 March 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):

Director

Title

Number of Ordinary Shares purchased

Price paid per Ordinary Share

Resultant beneficial holding

% of issued share capital

David Allmond

Chief Executive Officer

 

43,500

 

 

£2.31

 

43,500

 

0.06%

 

   

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 

David Allmond, Chief Executive Officer

 

2.

Reason for the Notification

a)

Position/status

See 1(a) - classified as a PDMR of the Company

 

b)

Initial notification/ Amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Novacyt S.A.

b)

LEI

213800BWAC2BF295EG28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of €1/15 each

 


Identification code

FR0010397232

b)

Nature of the transaction

Acquisition of Ordinary Shares

 

c)

Price(s) and volume(s)

 

Price

Volume

£2.31

43,500

d)

Aggregated information:

· Aggregated volume

· Price

 

Price

Volume

£2.31

43,500

 

 

e)

Date of the transaction

 

25 March 2022

f)

Place of the transaction

AIM

 

 

- End -

 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[email protected] / [email protected]

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

[email protected] / [email protected] / [email protected]  

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

[email protected]  

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information, please refer to the website: www.novacyt.com  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPUBGWUPPGMA

a d v e r t i s e m e n t